Mage Biotechnologies

What Mage Biotechnologies does

Mage Biotechnologies is a privately-held biotechnology company founded in 2017 and headquartered in London, United Kingdom. According to available firmographic data, the company focuses on regenerative medicine and innovative biotech solutions, placing it within the cell-and-gene-therapy and tissue-engineering sub-sector. The firm operates at a small scale, with a headcount band of 11-50 employees, consistent with an early- to mid-stage biotech operating prior to commercialization or in the early stages of pipeline development.

The company's primary web presence, magegroup.co.uk, rendered only a verification/loading page at the time of data collection and provided no substantive disclosure regarding specific product candidates, underlying scientific platform, pipeline assets, intellectual property, management team, partnerships, funding history, revenue, or commercial model. Consequently, no details about core technology (e.g., cell type, modality, delivery mechanism), preclinical or clinical stage, regulatory pathway, or go-to-market strategy can be substantiated from the input data.

From a business-model perspective, no pricing model, revenue mechanics, customer segments, or partnership structure is documented. There are no disclosed funding rounds, no named investors, and no parent-company or subsidiary relationships recorded. Given the opacity of the public information source, the available evidence supports only a baseline characterization: a UK-domiciled, small-team regenerative-medicine biotech founded in 2017 whose substantive operations, scientific platform, and commercial trajectory remain undisclosed in the data provided.

Name

Mage Biotechnologies

Website

https://magegroup.co.uk

Company type

Private

Founded year

2017

Headcount range

11–50 employees

Short description

Mage Biotechnologies is a London-based, privately-held regenerative medicine biotech founded in 2017, operating with an 11-50 employee team and no publicly disclosed pipeline, platform, or commercial details in the source data.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine
• Biotech therapeutics
• Cell therapy development
• Biomedical research
• Life sciences solutions

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel

Core offering

Mage Biotechnologies operates in regenerative medicine and innovative biotech solutions. The company develops biotechnology-based offerings aimed at advancing regenerative medicine applications. Specific product or service details were not available in the source data because the company's website displayed only a verification/loading page with no substantive content.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Direct peers

• Pluristem Therapeutics: Pluristem develops placenta-derived cell therapies for regenerative indications including muscle injury and bone marrow recovery. Comparable to Mage as a focused, cell-therapy-centric regenerative medicine developer operating at small scale.
• Athersys: Athersys is a clinical-stage regenerative medicine company developing cell therapies for inflammatory, neurological, and cardiovascular indications. Its pipeline-driven, asset-focused model mirrors what a small regenerative medicine private company like Mage would pursue.
• Mesoblast: Mesoblast develops allogeneic cellular medicines for inflammatory and musculoskeletal conditions, making it one of the closest direct comparables to a regenerative-medicine specialist of Mage's apparent profile. Both companies target tissue repair and regenerative mechanisms with cell-based therapies.
• Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic cell transplants for neurologic, oncologic, and orthopedic indications. Comparable to Mage as a clinical-stage regenerative medicine company with multiple cell-therapy programs targeting tissue regeneration.
• Capricor Therapeutics: Capricor is developing cell-derived exosome and cell therapy programs for Duchenne muscular dystrophy and other indications. Comparable to Mage as a small, specialized regenerative medicine company pursuing cell-based therapeutic mechanisms.

Broad incumbents

• Bristol Myers Squibb: BMS is a global pharmaceutical company with a substantial cell therapy franchise (Breyanzi, Abecma) following the Celgene/Juno acquisitions. Comparable as a broad incumbent with deep regenerative/cell-therapy capabilities and a history of acquiring pipeline-stage regenerative medicine companies.
• Vertex Pharmaceuticals: Vertex Pharmaceuticals has made major regenerative medicine moves including its acquisition of ViaCyte and its Casgevy launch. Comparable as a broad incumbent establishing a leadership position in regenerative cell therapies and a logical potential acquirer for companies like Mage.
• AstraZeneca: AstraZeneca is a UK-headquartered global pharmaceutical company with growing cell therapy and regenerative medicine ambitions. Comparable as a potential acquirer or co-development partner for a London-based regenerative medicine specialist like Mage, given its UK base and expanding ATMP interest.

Emerging players

• Fate Therapeutics: Fate Therapeutics develops programmed cellular immunotherapies using induced pluripotent stem cell (iPSC) technology. Comparable to Mage through shared underlying regenerative-medicine / engineered-cell-therapy technology base, though Fate focuses on immuno-oncology applications.
• BlueRock Therapeutics: BlueRock Therapeutics (a Bayer subsidiary) develops engineered cell therapies with focus on regenerative medicine, including pluripotent stem-cell-derived therapies. Comparable as a specialized cell therapy company in the regenerative space, though at substantially larger scale and with major-pharma backing.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/mage-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mage Biotechnologies